Reduce factory inventory by 50% before introducing Microbio μ3D.
Streamlining quality control and reducing costs through advanced microbial testing. Interview on the introduction of a rapid fully automated bacterial colony detection system.
We conducted an interview with Masashi Itakura, Executive Officer and Managing Director of Pigeon, a leading company in childcare products, which was quick to adopt the rapid fully automated bacterial colony detection system "Microbio μ3D." The "Microbio μ3D" continuously monitors the shadows of colonies on petri dishes every 30 minutes using a CCD camera. By detecting changes in shadows not only by area but also by volume, it enables faster detection of colonies growing on the medium compared to visual observation. 【Implementation Results】 - Reduced the determination period for fungi in microbial limit tests from 3-4 days, resulting in a 50% reduction in factory inventory. - Reduced human error in quality inspections and standardized the inspection process. - Streamlined and systematized inspection tasks, allowing a focus on creative work such as product development. *Please download the interview article from our company website. *For product information, feel free to download the PDF or contact us.
Inquire About This Product
basic information
*Please download the interview article from our company website. *For product information, feel free to download the PDF or contact us.
Price range
Delivery Time
Applications/Examples of results
*Please download the interview article from our company website. *For product information, feel free to download the PDF or contact us.
Company information
BD Japan is the Japanese subsidiary of BD, one of the world's leading medical device and medtech companies headquartered in New Jersey, USA. BD aims to lead the world in medical technology, seeking new insights in the healthcare field and improving the quality of diagnosis and treatment, with the purpose of realizing "The future of healthcare for all(TM)." By developing innovative technologies and services related to patient treatment and healthcare processes, BD supports those working on the front lines of healthcare. With approximately 77,000 employees worldwide, BD staff support researchers in the development of next-generation diagnostic and therapeutic methods and strive daily to enhance the safety of healthcare professionals and the efficiency of medical practices in clinical settings. By partnering with healthcare institutions in countries around the world and addressing global priority issues, BD contributes to improving healthcare outcomes, reducing costs, increasing efficiency, enhancing safety, and promoting access to healthcare through close collaboration with its customers, the healthcare institutions.